HC Wainwright & Co. Reiterates Buy on Biotricity, Raises Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Kevin Dede has reiterated a 'Buy' rating on Biotricity (NASDAQ:BTCY) and raised the price target from $2 to $4.
July 05, 2023 | 11:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biotricity's price target has been raised from $2 to $4 by HC Wainwright & Co., which maintains a 'Buy' rating on the stock.
The reiteration of a 'Buy' rating and a price target increase by a reputable analyst firm like HC Wainwright & Co. is typically seen as a positive signal by the market. This could lead to increased investor confidence in Biotricity, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100